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SYNTHESIS OF DOXORUBICIN-BASED PRODRUG AND ACTIVATABLE MR 
NANOPROBE FOR THE IMAGING AND TREATMENT OF CANCER 
 
 
An Abstract of the Thesis by 
Bayan Ahmad S Dous 
 
 
Magnetic Resonance Imaging (MRI) is increasingly being used as a diagnostic 
tool for cancer. We propose a novel molecular probe, Gadolinium-DTPA 
disulfide-bonded Doxorubicin (Gd-DTPA-SS-Doxo) encapsulated in iron oxide 
which could provide a dual modality for detecting malignant growth while 
simultaneously targeting treatment options. We first synthesized Gd-DTPA-SS-
Doxo followed by encapsulation within the poly (acrylic acid) (PAA) coating of 
iron oxide nanoparticle (IONP), producing a nanoprobe (IO-Gd-DTPA-SS-Doxo) 
with quenched longitudinal spin lattice magnetic relaxation (T1). After receptor-
mediated internalization, Gd-DTPA-SS-Doxo is released from the nanoprobe’s 
polymeric coating due to the acidic microenvironment of the tumor. When the 
molecular probe is subjected to various enzymes present in the cancerous cells, 
the disulfide bond of the molecular probe is cleaved. This results in an 
intracellular release of Gd-DTPA complex and Doxo with subsequent T1 
activation and cytotoxic effect respectively. Therefore, the proposed framework 
would give dual mode MR imaging of malignant growth, target ability and 
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SYNTHESIS OF DOXORUBICIN-BASED PRODRUG AND ACTIVATABLE MR 




Cancer is presently the second most basic reason for death in the U.S.  
As indicated by the American Cancer Society1 prostate cancer is anticipated to 
cause roughly 12 million deaths by 2030 1, 164,690 new cases are expected in 
2018, and 29,430 estimated deaths. Because of those huge numbers, scientists 
are focusing their studies trying to find a way to fight this disease. Currently 
practiced techniques such as radiation, surgery, hormone therapy, and 
chemotherapy are known to cause harm and damage to the healthy cells, risking 
the patients’ survival 2. For this reason; in 1980s, as an attempt to decrease the 
damage to healthy cells, scientists worked with nanoparticles (NPs), which were 
designed to target only the cancer cells 2. Considering the severity of prostate 
cancer, this work will focus on the development of magnetic nanotheranostics for 




Magnetic Resonance Imaging (MRI) is a technique employed in tissue 
imaging and clinical diagnosis of diseases. It permits visualization of tissues and 
organs, and also makes it possible to regenerate noninvasive sectional images3. 
In other words, molecular imaging techniques facilitate pathologic biomarker 
detection, thus, enhancing diagnosis of diseases and improved therapeutic 
management 3, 4, 6.  MRI has gained significant attention in the field of molecular 
imaging due to its numerous benefits, including short imaging times, high spatial 
resolution (µm-scale), impressive signal-to-noise (S/N) ratio, and its noninvasive 
characteristics 6. Biological processes, such as accumulation of lipids and 
angiogenesis signal the early development of some clinical conditions, are widely 
targeted by MRI contrast agents 4. In addition, MRI contrast agents target 
conditions, such as plaque rupture-induced tissue factors and fibrins; bio 
signatures that occur later. These contrast agents combine the benefits of 
therapeutic intervention and disease diagnosis since they can be used as 
vehicles for drug delivery 6.  MRI contrast agents are essential requisites in 
distinguishing healthy tissues from infected ones. Water is the primary 
constituent of living tissues; MRI primarily targets protons in the water by exciting 




Figure 1: Leading Sites of New Cancer Cases and Deaths – 2018 Estimates1. 
 
In practice, the water content in the tissues and the longitudinal rate of 
relaxation, R1 (in terms of 1/sec.), are proportional to the MRI signal; R1 describes 
the relaxation rate of the MRI signal during pulse sequencing 4. The protons in 
the body tissues are realigned with the magnetic field. An MRI scan stimulates 
the protons, which shift from equilibrium. From this excited state there are two 
forms of relaxation. The most rapid form of relaxation is the dephasing of the 
spins, this is known as T2 relaxation or transverse relaxation. This has the effect 
of reducing the overall magnetization vector in the XY plane. The second slower 
form of relaxation involves the return to equilibrium of spin up and spin down 
states, this is known as T1 relaxation or longitudinal relaxation. This has the 
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effect of restoring the overall magnetization vector in the Z direction. Such 
magnetic features make it possible to differentiate tissues 8.    
The polymer-coated iron oxide nanoparticles (IONPs) are polymer-coated 
and superparamagnetic, which are used to enhance the contrast of tomographic 
MR images from disease site and organs. The polymeric coating enhances the 
stability of IONPs in aqueous media9. IONPs decrease the MR signal (dark, 
negative contrast) of an MRI sequence that is T2-weighted, by reducing the 
transverse time of relaxation time T2 of the neighboring protons 11. So far, IONPs 
have proven to be the most desirable superparamagnetic agents in improving the 
contrast in T2 MR Scans. The choice of IONPs is often acknowledged by their 
minimal toxicity to cancer cells 5.  
Gadolinium complex (Gd-DTPA) is a paramagnetic metal chelate used as 
a MRI contrast agent. Its principle role is to reduce the water protons’ longitudinal 
time of relaxation, T1, thus enhancing the intensity of T1-weighted images (bright, 
positive contrast), which can be visualized by a radiologist 12. Gd-DTPA contrast 
agent comprises atoms and molecules that are closely-packed by strong 
chemical bonds between the chelating agent (DTPA) and Gd3+. Due to the high 
toxicity of Gd3+, the ions are often coupled with a chelating agent ensuring the 
magnetic property is retained. During a MRI scan, the contrast agent is injected 




The formulation of Gd-DTPA (diethylenetriamine pentaacetic acid) is 
essentially an activatable MRI nanoprobe encapsulated within an IONP to obtain 
a composite nanoprobe. In nanomedicine, both MRI contrast agents can be 
utilized in dual mode, as Gd-IONP. When exposed to acidic environments, the 
composite contrast agent is activated, thus, enhancing the T1 weighted signal 
(brighter contrast). The Fe2O3 core comprises magnetically-ordered pairs of Fe2+ 
and Fe3+ ions within the nanocrystal 9. The net magnetic moment exerted by the 
combination exceeds that of the single paramagnetic Gd3+, Fe2+ and Fe3+. In 
tandem, it is expected that the magnetic core will become susceptible to the 
intense magnetic moment created and subsequently, affect Gd-DTPA’s time of 
relaxation, T1. Further, it is expected that the composite magnetic nanoprobe will 
relax at a rate of 1/T1 when the Gd-DTPA complex is extracted from the 
polymeric coating of the nanoprobe to elicit dequenching 9.  
Many studies have been conducted over time and in one study (Scheme 
1) they reported a synthesis of an activatable prodrug (Doxo-SS-Fol), and also a 
nonactivatable probe (Doxo-CC-Fol) 13. They observed that due to a high GSH 
level in cancer cells the disulfide bond was cleaved leading to the activation of 
fluorescence emission and cytotoxicity. On the other hand, it remains OFF when 





Scheme 1: Doxorubicin-based activatable prodrug for the targeted treatment of 
lung cancer13. 
 
To track the final localization of the prodrug cells, the presence of the 
folate receptor and the final localization of the conjugate in cultured cells, many 
folate conjugation with nanoparticles and fluorescent dyes have been developed 
and used 13. In (Scheme 1B), it was found that when the prodrug is linked with 
carbon-carbon covalent bond; the fluorescence and cytotoxicity of the 
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doxorubicin are quenched (OFF). on the other hand, it became activated (ON) 
when the linkage is done with a disulfide bond (S-S), dithiobis (succinimidyl 
propionate) (DSP) were in the design of the conjugation (Scheme 1A); linking 
the cytotoxic doxorubicin and the targeting folate unit. So, upon interaction and 
by using a specific enzyme associated with disease, an activatable molecular 
imaging agent becomes activated; an increase was noticed in its signal output14. 
This allows the lower signal background and the image resolution to increase. In 
the meantime, when the prodrug is less toxic it enters the sick cells and became 
active 13. In this study, the folic acid can act as both a quencher for the 
doxorubicin and a receptor targeting ligand (Scheme 1).  
In the study15, they designed the prodrug Lac-SS-DCM created with a 
disulfide bond unit and an alkyne reaction group. It reduces the side effects and 
gives higher anticancer effectiveness as well as excellent target ability. The 
multivalent galectin-targeting ligand was performed when lactose-mediated 
endocytosis resulting from the surface lactose corona15. The quenching of the 
strong NIR fluorescence light of the compound Lac-SS-DCM was done via the 
newly formed amide bond.  In addition, taking advantage of the disulfide bond (-
SS-) the prodrug causes disband by the enzyme (GSH), which makes the drug to 




Scheme 2: Prodrug Lac-SS-DCM15 for the treatment of cancer. 
 
In a different study16, they provide a design with multimodal probe which 
was very active tool for repaid and giving the imaging of the biological steps. This 
special design can show multiplex imaging signals due to the interaction with the 
specific molecules in the design. They studied and reported that the design 
follows a stimuli-responsive disassembly approach and has three sides as shown 





Scheme 3: The concept behind the design of an activatable probe16. 
 
Santra e t. al., developed novel activatable MR probe by encapsulating 
Gd-DTPA complex in iron oxide nanoparticles (IONPs) for the imaging and 
treatment of cancer5. It was found that the Gd’s T1 MR contrast was dequenched 
(activated) after releasing the Gd-DTPA complex inside the cancer cells, 
facilitating for an activatable T1 MR images for diagnosis5.  
 
Scheme 4: composite magnetic nanoprobe IO-PAA-Gd-DTPA and 
corresponding T1 MR Activation5. 
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The aim of this study is to utilize the Gd-DTPA and IONPs (Fe2+ + F3+) 
carrier molecules as a dual mode MRI nanoprobe for treatment and imaging of 
cancer. In this study (Scheme 5A), we are proposing a Doxo-SS-Gd-DTPA 
nanoprobe encapsulating IONPs for the MR imaging and treatment of cancer. 
We hypothesized that the disulfide bond of Doxo-SS-Gd-DTPA will be cleaved by 
GSH enzyme, when it enters into the cancer cells. After cleavage, Doxo and Gd-
DTPA will be released, where Doxo will lead to killing the cells and Gd-DTPA will 
act as T1 MR bright contrast. Along with the contrast and anticancer property, we 
introduced folate surface functionality, which would help in specifically targeting 
cancer cells. Further, the probe will remain inactive (prodrug) when it is in the 
blood stream because the level of the GSH is lower (1-10 μM) in the blood 
stream; and it is high in the cancer cells (1-10 mM) So, the same probe in the 





Scheme 5: (A) The representation of the proposed activatable MR nanoprobe-
prodrug. (B) Schematic diagram of the mechanism of action T1 and T2 MR 



















RESULT AND DISCUSSION 
 
 
In this study, we introduced a new cleavable Doxo-SS-Gd-DTPA prodrug; which 
will be used as a therapeutic agent in conjunction with T1 and T2 imaging for 
cancer. This prodrug will be encapsulated within PAA polymer coating of IONP-
Fol, a typical T2 agent. This would result in the quenching of gadolinium’s T1 
signal due to the proximity of iron oxide. The folate on the surface of IONP helps 
in recognition of the cancer cells from the healthy cells because most of the 
cancer cells overexpress folate receptors. Thereby, the prodrug is targeted to the 
tumor site. However, upon target recognition, the PAA coating will be disrupted 
by the tumor’s low pH microenvironment, followed by the prodrug Doxo-SS-Gd 
release. In addition, the released prodrug will be exposed to higher GSH level in 
the cytosol, which will cleave Doxo and Gd-DTPA complex from the Doxo-SS-
Gd-DTPA prodrug. This would lead to an enhanced toxicity from Doxo and 
activatable T1 MR signal from the Gd-DTPA complex. Hence, the proposed 
system would provide dual-mode MR imaging of cancer, targetability as well 
treatment for cancer.  
13 
 
Synthesis of DOXO-SS-Gd-DTPA:  Doxorubicin and Gadolinium in the Doxo-
SS-Gd-DTPA complex is useful for treatment and imaging, respectively. 
Magnetic resonance imaging (MRI) technology is often implemented in the 
clinical diagnosis of illnesses and animal imaging 8. 
  
Scheme 6: The synthesis and the mechanism of the activatable prodrug. 
 
The Gd-DTPA complex was synthesized using reported protocol8 prior to the 
molecular probe synthesis (Doxo-SS-Gd-DTPA), and dissolved in water. T1 and 
T2 MR values were measured and dilution was carried out until desired T1 and 
T2 values were achieved. Furthermore, Doxo was conjugated to Gd-DTPA 
complex using DSP cross-linker. The NH2 group on Gd-DTPA complex and Doxo 
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gets attached to the DSP linker in presence of Et3N in order to synthesize 
activatable Doxo-SS-Gd-DTPA complex in solution (Scheme 6). When this probe 
will enter the cancer cells the S-S bond will break due to a high level of 
glutathione in cancer cells. This solution was further characterized and then 
encapsulated in IONP. 
Characterization of Doxo-SS-Gd-DTPA: After preparation of Doxo-SS-Gd-
DTPA solution, the absorbance and fluorescence intensity were measured for 
detecting the presence of Doxo. An absorbance peak for the free Doxo and free 
molecular Doxo-SS-Gd-DTPA probe was detected at 495 nm (Figure A). 
Although there was a slight decrease in the intensity of free molecular probe, the 
absorbance wavelength was similar to that of free Doxo. After measuring the 
absorbance, the fluorescence intensity was also measured for both free Doxo 
and free molecular probe which was at 595 nm (Figure B). Again, there was a 
slight decrease in the intensity of free molecular probe because Doxo is 








Moving forward, T1 and T2 values were taken for the same sample; T1 value 
was measured to be 53.43 ms (Figure C) which is a very strong signal for T1, 
whereas T2 was 700 ms (Figure D) indicative of the weak T2 MR property of the 
molecular probe.  
 
Figure 2: (A) Comparison between free Doxo and the molecular probe UV.      
(B) Comparison between free Doxo and the molecular probe fluorescence.     
(C), (D) MR Data of molecular probe before encapsulation. 
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Synthesis of iron oxide nanoparticles (IONP):  Iron oxide nanoparticles 
(IONP) has attracted large interest due to their superparamagnetic property. 
Some common uses of synthesized nanoparticles include high-sensitivity 
bimolecular MRI, catalysis, superparamagnetic relaxometry (SPMR), and 
sensors20. Herein, we formulated iron oxide nanoparticle using solvent 
precipitation method. For performing the synthesis of IONP, three different 
solutions of i) iron salts solution, ii) poly acrylic acid (PAA) solution, and iii) 
ammonium hydroxide (NH4OH) solution were prepared. First, the iron salts 
solution was added to NH4OH solution with constant mixing using vortex, and 
then PAA solution was added to stabilize the iron oxide nanoparticles. After 
carrying out the entire reaction, the resultant IONP solution was centrifuged to 
bring it to the desired size. Further, the solution was purified using dialysis 








Table 1: Molecular probe before encapsulation MR Data and Nanoprobe after 
encapsulation MR Data.  
 
Molecular and nano  prodrug T1 (ms) T2 (ms) 
Doxo-SS-Gd 53.43 700 




Figure 3: (A) After encapsulation UV for Doxo-SS-Gd-DTPA-IONPs. (B) After 
encapsulation fluorescence for Doxo-SS-Gd-DTPA-IONPs. (C), (D) Nanoprobe 
after encapsulation MR Data.  
 
The synthesized Doxo-S-S-Gd-DTPA was also characterized using Bruker’s 
Microflex MALDI-TOF spectrometer using dihydrobenzoic acid as matrix. A 
detected a peak at 1210 Da, which corresponds to the (M-5H) + peak. It indicates 
that 5 protons were eliminated from DTPA during the ionization process (Figure 






Figure 4: MALDI-TOF spectrum of Doxo-S-S-Gd-DTPA prodrug. 
 
Synthesis of activatable magnetic nanoprobe: After the preparation of IONPs 
and Doxo-SS-Gd-DTPA solutions, the nanoprobe was formulated. Doxo-SS-Gd-
DTPA complex was encapsulated into PAA coatings of IONPs, using solvent 
diffusion technique. After the encapsulation, pure solution of IONP-PAA-Doxo-
SS-Gd-DTPA was obtained by dialysis technique and conjugation with folate was 
carried out to achieve surface functionality. As most of the cancer cells have 
folate receptor overexpression, folic acid was used as a targeting ligand for 
prostate cancer. The functionalization was carried out using EDC/NHS bio 
conjugation chemistry (Scheme 7). First, EDC solution was added to IONP-PAA-
Doxo-SS-Gd-DTPA complex followed by addition of NHS and PEG-Folate. 
Therefore, a solution of IONP-PAA-Doxo-SS-Gd-DTPA-Fol (nanoprobe) was 




Characterization of Functional nanoprobe: Post encapsulation within IONPs 
was characterized using UV/Vis and fluorescence measurement, which shows 
peaks at 485 and 495, respectively. These values were similar to what we 
observed prior to encapsulation, indicating that there is no major change in the 
characteristics after encapsulating Doxo-SS-Gd-DTPA complex in the IONPs. To 
check the magnetic property of the nanoprobe, we quantified MR signals which 
were found to be 139 ms and 79 ms of T1 and T2 values individually (Table 1). 
The reason for the change in T1 and T2 before and after encapsulation is 
because this T1 MR activatable prodrug’s signal would be (Doxo-SS-Gd-DTPA) 
quenched in presence of IONP (strong T2 agent). However, when the prodrug 
enters the body a strong T1 signal could be noticeable only in the acidic 
microenvironment of tumor where it gets activated.  
Furthermore, the presence of folate on the surface after conjugation was 
detected by UV Vis and fluorescence. The absorbance wavelength was abs = 
365 nm and the fluorescence was em = 452 nm after surface conjugation with 
folate (Figure 5D & B). The wavelength of absorbance and fluorescence 
intensity were comparative to that of free folic acid depicting there is no change 




















Figure 5: Surface conjugation with folate UV (A) Free folic acid, (B) Doxo-Fol. 





Characterization studies: The hydrodynamic size and zeta potential of IONP-
COOH, Doxo-SS-Gd-IONPs, and Doxo-SS-Gd-IONPs-Fol were determined with 
the help of DLS. According to the results (Figure 6), the size of IONP-COOH was 
noted to be 66.57 nm, while Doxo-SS-Gd-IONPs size was increased to 72.26 nm 
due to its encapsulation. After folate conjugation on the surface of Doxo-SS-Gd-
IONPs, the hydrodynamic diameter was amplified to 75.91 nm. Increase in size 
portrays the presence of a huge functional group on the surface. Zeta potential of 
the solutions was also determined along with the hydrodynamic diameter. The 
surface zeta potential of IONP-COOH was noted to be -32.7 mV because of the 
negativity of -COOH group. Whereas, the surface charge for Doxo-SS-Gd-IONPs 
was determined to be -26.6 mV and that of nanoprobe conjugated with the folate 
had a zeta potential of -38.4 mV. Hence, the change in zeta potential before and 





Figure 6:  Determination of size and zeta potentials of the functional   
nanoprobes. 
 
In-vitro Cell viability (MTT assay):  MTT assay is a colorimetric assay which 
helps to find out the cytotoxicity of drug by determining the cell viability. In the 
presence of mitochondrial reductase of healthy cells, MTT solution turns to 
formazan crystals (purple colored compound). The yellow colored MTT solution 
when added to the nanoprobe treated cells changes to purple color indicating the 
cells viability. Depending on the density of the color, we could determine how 
23 
 
many cells are viable. In here, we used this cell based assay in determining the 
cytotoxicity of IONP-Doxo-SS-Gd-DTPA probe on LNCaP cells. Different time 
points were selected for conducting the experiment. Initially, we seeded the cells 
in a 96 well plate and then treated them with different composition of nanoprobe 
encapsulated in IONPs. As see in (Figure 7), after 24 h treatment, IONP-Doxo-
SS-Gd-DTPA-Fol show 60 % cell viability whereas IONP-Doxo-Fol have 70 % 
cell viable. When relating this result with IONP-Gd-DTPA-Fol, it has 80% cells 
viable showing minimal cytotoxic effect. The cytotoxicity study at 36 h displayed 
the cell viability after treatment with IONP-Doxo-SS-Gd-DTPA-Fol was as low as 
35% whereas with IONP-Doxo-Fol was approximately 40%, which was fairly 
close to the cytotoxicity value of the former. 
 





The cell viability after treating with IONP-Gd-DTPA remained pretty constant 
proving that it does not play a major role in the cytotoxicity. At 48 h, treatment 
with IONP-Doxo-SS-Gd-DTPA-Fol resulted in the viability to be least, suggesting 
maximum cell death. Similar cytotoxicity was also observed with IONP-Doxo-Fol 
while IONP-Gd-DTPA-Fol showed very low cytotoxicity. Conclusively, IONP-
Doxo-SS-Gd-DTPA-Fol probe was effective in killing the cancer cells over time. 
As a negative control, the same assay was performed on PC-3 cells and the 
viability of cells were found to be consistent at all-time points. This indicates that 
the nanoprobe designed was specific to LNCaP cells.  
Cell Internalization Studies: Following the MTT assay, the nanoprobes ability to 
enter the cancerous cells were visually determined by performing cellular uptake 
study. After 12 h of treatment with the nanoprobe (Figure 8A-D), we observed 
cytoplasm was stained red due to the fluorescence effect of Doxo whereas the 
nucleus was stained blue with DAPI dye suggesting the internalization of 
nanoprobes into the LNCaP cells. As in Figure 8E-L, at 24 h and 48 h, the 
amount of cell viability decreased drastically indicating the cytotoxic effect of 
Doxo on LNCaP. When similar cell uptake study was done with PC-3 cells, there 
was negligible entry of the nanoprobe proving the specificity of the nanoprobe to 




  Figure 8: Cellular toxicity and viability of MR activatable nanoprobe. 
We performed activation study at different pH for different concentration of Gd 
encapsulated in nanoprobe at 0 h and 24 h. We can notice from  Figure 9 that 
increase in Gd concentration, Δ1/T1 value was increased and maximum T1 MR 
activation was observed at pH 4.0-5.0. This also indicated that the signal is 
directly proportional to the concentration and related to change in pH. Parallelly, 
Δ1/T2 value was plotted for different concentration of Fe at different pH and 
found that there was minimal change in T2 MR signal between these different 
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groups. In conclusion, the synthesized nanoprobe was T1 MR activatable and 
cytotoxic in vitro.  
 
Figure 9: Evaluation of magnetic activation of Doxo-SS-Gd-DTPA-IONPs-Fol 
using   Bruker’s magnetic relaxometer. 
 
MRI-Based T1-Weighted Activation of the Composite Nanoprobe: We 
studied if the observed pH-dependent increases in R1 (1/T1) of the nanoprobe 
results leads to increases in the T1-weighted signal in MRI, which leads to an 
increase in the brightness of the image. This would be one-step closer to the 
application of our nanoprobe for the cancer imaging application. For this, we took 
the different concentrations of our prodrug encapsulating IONPs and used 9T 
clinical MRI instrument for the T1 and T2 MR scanning at pH 5.0 (Figure 10). 
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The T1-weighted MR signals were increased as the concentrations of the 
activatable nanoprobes increase (from 0.75 to 6.0 μM of Gd), which reflected in 
the increase in T1 signals of the corresponding MR images (Figure 10A). This is 
indicative of the T1 MR signal activation at the lower pH. However, the T2 MR 
signal was not quenched, rather the images were darker as the iron 
concentrations increased (Figure 10B).   
 
Figure 10: Magnetic resonance imaging (MRI) studies measuring the T1 MR 






















METHODS AND EXPERIMENTAL SECTION  
 
 
Synthesis of PAA coated IONPs:  Iron oxide nanoparticles (IONPs) coated with 
PAA were synthesized using “water-based precipitation method”. To synthesize 
PAA coated IONPs, three solutions were prepared: i) Iron salts solution (0.7 g of 
FeCl3.6 H2O and 0.4 g of FeCl2 .4H2O in 100 μL of 12 N HCl and 2 mL of DI H2O), 
ii) an alkaline solution (1.8 mL of 30% NH4OH solution in 15 mL of deionized water) 
and iii) stabilizing agent solution (2 g of PAA in 5 mL of DI water). The synthetic 
procedure was as follows: The solution of iron salts was added into alkaline 
solution. Afterwards, stabilizing agent (PAA in DI water) was added to the above 
solution and the reaction was continued at a speed of 4000 rpm. Then, the resulting 
IONPs were centrifuged at 3000 rpm, 4000 rpm and 4000 rpm for 20 min each, 
respectively. The supernatant obtained after the final centrifugation was dialyzed 
in a dialysis bag, which has a molecular weight cut off range of 6-8 kDa. The 
dialysis process was done in beaker with DI water and a magnetic stirrer. The water 
was changed periodically for 24 h and the dialyzed IONPs were taken out of 




Synthesis of the Gd-DTPA:  Gd-DTPA is a highly stable paramagnetic complex 
which was synthesized by adding a solution of gadolinium chloride hexahydrate 
(GdCl3.6H2O) in a solution of diethylenetriaminepentaacetic acid (DTPA). 4.49 g 
of GdCl3.6H2O was dissolved in 10 mL of deionized water to make a molar 
concentration of 0.0121 M. Then, DTPA of 5.0 g was dissolved in 30 mL of water 
containing 2 N NaOH (5.0 mL) solution to form 0.0127 M solution of DTPA. These 
prepared stock solutions of gadolinium and DTPA were mixed together by 
dropwise addition of GdCl3.6H2O solution to DTPA solution. Thereafter, 2 N NaOH 
was continuously added to the above solution to bring the pH to 6.8 and the 
reaction was maintained at 80C for 12 h. This reaction led to the formation of 
white crystals which were initially dissolved little amount of water followed by 
precipitation with ethanol. Once precipitated the solution was filtered to remove the 
Gd-DTPA complex and dried under vacuum 
Encapsulation of Gd-DTPA-IONPs:  In a 15 mL tube, we took 5 mL of the freshly 
prepared IONP and then we added 500 μL of Gd-DTPA drop by drop at 1200 rpm 
on vortex mixer. It was allowed to mix in the orbital mixer overnight and then T1 
and T2 values were detected. 
Synthesis of Doxo-SS-Gd-DTPA: Doxorubicin hydrochloride salt was made into 
an aqueous solution and added to PBS buffer solution of pH 7.4 to form amine free 
doxorubicin. This was allowed to centrifuge and the supernanant was removed. 
The solid pellet from the centrifugate was dissolved in dimethyl sulfoxide (DMSO) 
forming doxorubicin solution. 1.84 mM solution of dithiobis (succinimidyl 
propionate) (DSP) was added dropwise to a mixture containing solution of Gd-
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DTPA complex solution and doxorubicin solutions. To this above mixture, a small 
amount of triethylamine (0.4 μL in DMSO) was added at 25C for 30 mins, followed 
by incubation overnight at 4C. The synthesized probe was finally characterized 
using various spectroscopic methods including MALDI-TOF. 
MALDI Matrix Preparation: 
1. Preparation of TA30 Solvent:  
TA30 is a 30:70 (vol/vol) mixture of acetonitrile (ACN): trifluoroacetic acid 
(TFA) in deionized water. First, the acid solution was diluted, then 
combined with 300 μL AcN + 699.3 μL deionized water + 0.7 μL TFA = 1 
mL TA30. 
2. Matrix Solubilization:  
Add 2, 5-Dihydroxybenzoic acid (20 mg/mL) to the TA3O solution and 
vortex until dissolved.  
3. Sample Preparation:  
Nanoprobe was dissolved in methanol of 50 mg/mL.  
4. Sample Plating:  
Equal volumes of matrix solution and nanoprobe solution were taken into 
a new tube and vortexed for a few minutes until thoroughly mixed. Then, 
0.5 μL drop of this solution was placed on the MALDI plate. The sample 





Cytotoxicity assay (MTT):  For estimating the toxicity of the nanoprobe, MTT 
assay was performed. LNCaP cells were seeded on a 96 well plate for 24 hours 
and stored at 37°C. On the next day, they were treated with IONP-Gd-Fol, IONP-
DOXO-Fol and IONP-Doxo-SS-Gd-DTPA-Fol, which was incubated for 12, 24, 
36 and 48 hours. Following the respective treatment period, 30 μL MTT solution 
was added in each well and again stored for 4-6 hours. This helped in formation 
of purple formazan crystals which could help us in determining the live cells. To 
dissolve the purple color formazan, acidic isopropyl solution was added and kept 
on thermo-mixture overnight. Finally the fluorescence was measured at 570 nm 
using a plate reader and results were plotted. 
Magnetic relaxation: Magnetic relaxation of different samples were performed 



























We designed and synthesized an activatable doxorubicin-based prodrug Doxo-S-
S-Gd-DTPA and characterized it using various spectroscopic methods. This 
prodrug was encapsulated in PAA-coated IONPs and characterized. The IONP-
PAA-Doxo-SS-Gd-DTPA-Fol nanoprobe, which quenches T1 signal (low ∆1/T1), 
when at close vicinity to the strong T2 agent IONP. Upon release of Doxo-SS-
Gd-DTPA from the nanoprobe complex, ∆1/T1 was increased indicating 
quenching effect. This release of the T1 agent from the IONP-based nanoprobe 
complex leads to improved MRI contrast. Though the release of the Doxo-SS-
Gd-DTPA altered T1 signal, it had only minimal effect on T2 signaling.  
Next, we performed cell uptake study in order to assess the specificity of the 
nanoprobe to the LNCaP cells, which targeted only cancerous cells because of 
the functionalization with folate on the IONPs. Once internalized, the nanoprobe 
complex was dissociated due to the presence of glutathione, where Doxo-
complex enhanced cytotoxic effect and Gadolinium-complex was helpful in MR 
imaging. To assess the cytotoxic capability of the nanoprobe MTT assay was 
performed, which showed that after nanoprobe treatment less viable cells were 
present at 48 h. The activation study was performed which presented that the 
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activation of nanoprobe varied with concentration and pH, showing maximum 
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